Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) from a buy rating to a hold rating in a report published on Saturday morning.

Other equities research analysts have also recently issued research reports about the company. Royal Bank Of Canada raised their price objective on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the company a “sector perform” rating in a research note on Tuesday, February 24th. Weiss Ratings raised Lakefront Biotherapeutics American Depositary Shares from a “sell (d)” rating to a “hold (c)” rating in a research report on Thursday, February 26th. Raymond James Financial reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, February 24th. UBS Group reissued a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Finally, Zacks Research downgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Lakefront Biotherapeutics American Depositary Shares has a consensus rating of “Hold” and an average target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Price Performance

LKFT stock opened at $27.05 on Friday. The stock has a market capitalization of $1.78 billion, a PE ratio of -19.18 and a beta of 0.25. The company’s 50-day moving average is $29.73 and its 200-day moving average is $31.62. Lakefront Biotherapeutics American Depositary Shares has a 1 year low of $26.62 and a 1 year high of $37.78.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its earnings results on Sunday, February 15th. The biotechnology company reported $13.92 EPS for the quarter. The firm had revenue of $1.06 billion during the quarter. On average, analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

Institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its position in Lakefront Biotherapeutics American Depositary Shares by 2.1% in the 3rd quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock valued at $1,072,000 after buying an additional 643 shares during the last quarter. Van ECK Associates Corp grew its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% in the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 750 shares in the last quarter. Two Sigma Investments LP grew its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 3.7% in the 3rd quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock worth $778,000 after acquiring an additional 800 shares in the last quarter. State of Wyoming purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter valued at about $28,000. Finally, Arax Advisory Partners raised its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% in the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 1,778 shares during the last quarter. Institutional investors own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.